Videos

Insights into current practice of global pharma labeling, including shortcomings and potential improvements.

Innovations in Global Pharma Labeling

While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials. Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise. In this video, we dive deep into the expanded use of registries as external control arms in clinical trials.

Deep Dive into the Use of Real-World Registry Data as External Control Arms

Reactions and top-of-mind concerns regarding digitalization and the collection and review of data used to shape patient-centric healthcare.

Creating Solutions within Healthcare Ecosystems to Improve Patient Outcomes

Pharmaceutical Executive, in collaboration with Biofourmis, organized a roundtable of experts from various groups to discuss how digital medicine and pharmaceuticals are changing the trajectory of what drug development and clinical care look like together, with an emphasis on partnerships within digital health.

Digital Medicine and Pharma: The Partnerships Bringing Together Molecule and Software

Understanding today’s real-world evidence-driven research questions and the real-world data that can provide answers.

Richard Young, Vice President of Strategy, Vault CDMS and Tim Davis, Vice President of Strategy, MyVeeva for Patients, discuss the future of digital trials and their impact in the industry. 

The Changing Landscape of Digital Trials

 Imaging is an integral part of many clinical studies, particularly in the fields of oncology and ophthalmology. Learn why imaging and centralized review are essential for clinical trials, how to address challenges that arise in these studies, and the advantages of partnering with MERIT in this video.  

The Importance of Imaging and Centralized Review in Clinical Trials

Defining what Gross-to-Net mean and why it is important to Life Sciences companies; Identify who in the company benefits in utilizing information from GTN; Get insights to successfully define and manage GTN process

Gross-to-Net is not just a process but a way for business growth

In this video Akeel Williams, VP of Strategy and Operations, Manufacturer Solutions, explains how GoodRx uses data to continuously improve its platform for patients and providers.


Creating Data-driven, Personalized User Experiences

As life science organizations continue to leverage both real world data [RWD] and real-world evidence [RWE] in the product approval landscape, a more nuanced understanding of both RWD and RWE is needed. Given the expansive types of data available now, understanding which data set is needed and how it should be analyzed is decidedly valuable. Our expert provides basic tenets for consideration

Sponsored Videos